Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents Insights of the TROFI II Trial

被引:26
|
作者
Gomez-Lara, Josep [1 ]
Brugaletta, Salvatore [2 ]
Ortega-Paz, Luis [2 ]
Vandeloo, Bert [1 ]
Moscarella, Elisabetta [2 ]
Salas, Miguel [1 ]
Romaguera, Rafael [1 ]
Roura, Gerard [1 ]
Ferreiro, Jose L. [1 ]
Teruel, Luis [1 ]
Gracida, Montserrat [1 ]
Windecker, Stephan [3 ]
Serruys, Patrick W. [4 ]
Gomez-Hospital, Joan-Antoni [1 ]
Sabate, Manel [2 ]
Cequier, Angel [1 ]
机构
[1] Univ Barcelona, Hosp Univ Bellvitge, Inst Invest Biomed Bellvitge, Dept Intervent Cardiol, Lhospitalet De Llobregat, Spain
[2] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain
[3] Bern Univ Hosp, Dept Cardiol, Bern, Switzerland
[4] Imperial Coll London, Natl Hlth & Lung Inst, Int Ctr Circulatory Hlth, London, England
关键词
bioresorbable vascular scaffolds; drug-eluting stent(s); endothelial dysfunction; optical coherence tomography; ST-segment elevation myocardial infarction; ST-SEGMENT-ELEVATION; ACUTE MYOCARDIAL-INFARCTION; MICROCIRCULATORY RESISTANCE; MICROVASCULAR OBSTRUCTION; PRIMARY ANGIOPLASTY; VASCULAR SCAFFOLDS; PROGNOSTIC VALUE; IMPLANTATION; DYSFUNCTION; THERAPY;
D O I
10.1016/j.jcin.2018.04.026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The study sought to compare the vasomotor and microcirculatory function of the infarct-related artery (IRA) between bioresorbable vascular scaffolds (BVS) and everolimus-eluting stents (EES) at 3 years. BACKGROUND The ABSORB STEMI TROFI II study showed similar outcomes between BVS and EES in the context of ST-segment elevation myocardial infarction at 3 years. METHODS Sixty-three consecutive event-free patients of the randomized TROFI II study were screened to undergo coronary angiography with vasomotor, microcirculatory, and optical coherence tomography (OCT) examination at 3 years. Vasomotion was defined as >4% change in mean lumen diameter to acetylcholine (ACH) and nitroglycerin as assessed by quantitative angiography. Microcirculatory examination was performed with pressure or thermodilution techniques. RESULTS A total of 38 patients (20 BVS and 18 EES) were included. At 3 years, >= 60% of patients exhibited paradoxical vasoconstriction to ACH in the periscaffold or stent segments. Vasoconstriction to ACH and vasodilatation to nitroglycerin were more often observed in the scaffold or stent segment with BVS than with EES (77.8% vs. 25.0%; p = 0.008 and 61.1% vs. 18.8%; p = 0.018). The IRA-depending microcirculation showed similar index of resistance (23.8 vs. 22.4; p = 0.781), coronary flow reserve (2.4 vs. 1.9; p = 0.523), fractional flow reserve (0.91 vs. 0.93; p = 0.317), and absolute flow (135.5 ml/min vs. 147.3 ml/min; p = 0.791). OCT showed remaining strut footprints and larger number of intraluminal scaffold dismantling (26.3% vs. 0%; p = 0.049) in the BVS group. CONCLUSIONS Both endothelium-dependent and -independent vasomotion of the IRA were more evident with BVS, as compared with EES, at 3 years. Functional microcirculatory parameters were mostly adequate and similar between BVS and EES. Clinical implications of these findings warrant further investigations. (c) 2018 by the American College of Cardiology Foundation.
引用
收藏
页码:1559 / 1571
页数:13
相关论文
共 50 条
  • [1] Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents
    Sorrentino, Sabato
    Giustino, Gennaro
    Mehran, Roxana
    Kini, Anapoorna S.
    Sharma, Samin K.
    Faggioni, Michela
    Farhan, Serdar
    Vogel, Birgit
    Indolfi, Ciro
    Dangas, George D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (25) : 3055 - 3066
  • [2] Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease
    Ellis, Stephen G.
    Kereiakes, Dean J.
    Metzger, D. Christopher
    Caputo, Ronald P.
    Rizik, David G.
    Teirstein, Paul S.
    Litt, Marc R.
    Kini, Annapoorna
    Kabour, Ameer
    Marx, Steven O.
    Popma, Jeffrey J.
    McGreevy, Robert
    Zhang, Zhen
    Simonton, Charles
    Stone, Gregg W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (20): : 1905 - 1915
  • [3] A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan
    Kimura, Takeshi
    Kozuma, Ken
    Tanabe, Kengo
    Nakamura, Sunao
    Yamane, Masahisa
    Muramatsu, Toshiya
    Saito, Shigeru
    Yajima, Junji
    Hagiwara, Nobuhisa
    Mitsudo, Kazuaki
    Popma, Jeffrey J.
    Serruys, Patrick W.
    Onuma, Yoshinobu
    Ying, Shihwa
    Cao, Sherry
    Staehr, Peter
    Cheong, Wai-Fung
    Kusano, Hajime
    Stone, Gregg W.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (47) : 3332 - 3342
  • [4] Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials
    Mahmoud, Ahmed N.
    Barakat, Amr F.
    Elgendy, Akram Y.
    Schneibel, Erik
    Mentias, Amgad
    Abuzaid, Ahmed
    Elgendy, Islam Y.
    [J]. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2017, 10 (05)
  • [5] Mid- and Long-Term Outcome Comparisons of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents A Systematic Review and Meta-analysis
    Zhang, Xin-Lin
    Zhu, Qing-Qing
    Kang, Li-Na
    Li, Xue-Ling
    Xu, Biao
    [J]. ANNALS OF INTERNAL MEDICINE, 2017, 167 (09) : 642 - +
  • [6] Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds
    Puricel, Serban
    Arroyo, Diego
    Corpataux, Noe
    Baeriswyl, Gerard
    Lehmann, Sonja
    Kallinikou, Zacharenia
    Muller, Olivier
    Allard, Ludovic
    Stauffer, Jean-Christophe
    Togni, Mario
    Goy, Jean-Jacques
    Cook, Stephane
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (08) : 791 - 801
  • [7] Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials
    Cassese, Salvatore
    Byrne, Robert A.
    Ndrepepa, Gjin
    Kufner, Sebastian
    Wiebe, Jens
    Repp, Janika
    Schunkert, Heribert
    Fusaro, Massimiliano
    Kimura, Takeshi
    Kastrati, Adnan
    [J]. LANCET, 2016, 387 (10018): : 537 - 544
  • [8] Coronary artery aneurysms formation within Everolimus-eluting stents and bioresorbable vascular scaffolds
    Lee, Wei-Chieh
    Chung, Wen-Jung
    Fang, Hsiu-Yu
    Wu, Chiung-Jen
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 206 : 58 - 60
  • [9] Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial
    Diego Arroyo
    Mario Togni
    Serban Puricel
    Baeriswyl Gerard
    Lehmann Sonja
    Noé Corpataux
    Hélène Villeneuve
    Estelle Boute
    Jean-Christophe Stauffer
    Jean-Jacques Goy
    Stéphane Cook
    [J]. Trials, 15
  • [10] Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial
    Arroyo, Diego
    Togni, Mario
    Puricel, Serban
    Gerard, Baeriswyl
    Sonja, Lehmann
    Corpataux, Noe
    Villeneuve, Helene
    Boute, Estelle
    Stauffer, Jean-Christophe
    Goy, Jean-Jacques
    Cook, Stephane
    [J]. TRIALS, 2014, 15